Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056506 | 1.00 | ESR1 (0.73) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL3056503 | 1.00 | ESR1 (0.73) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL3048572 | 1.00 | ESR1 (0.73) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL1659833 | 0.91 | ESR1 (0.86) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL4970901 | 0.91 | CYP1B1 (0.82) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL4970910 | 0.91 | CYP1B1 (0.82) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL3003461 | 0.91 | CYP1B1 (0.82) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL1659832 | 0.91 | ESR1 (0.86) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL3003462 | 0.91 | CYP1B1 (0.82) | ESR1ESR2CYP1B1MAPTMEN1 | |
| SCHEMBL16810359 | 0.86 | ESR1 (0.73) | ESR1ESR2CYP1B1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8192717-B2 | Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening | NAGASAKI UNIVERSITY (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | NAGASAKI UNIVERSITY (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2030635-A1 | COMPOSITION FOR DIAGNOSING AMYLOID-RELATED DISEASE | Nagasaki University (JP) | 2009-03-04 | — | — | EP | disclosed |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | Mori, Hiroshi (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1815872-A1 | COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS | Nagasaki University (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | APP, APBA1, FABP7 | ESR1 3158/4885ESR2 2805/4885CYP1B1 1467/4885 |
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | APP, FABP7, APBA1 | ESR1 4344/4885ESR2 1610/4885CYP1B1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.